FLUORESCENCE DETECTION OF ANTI CANCER DRUG TOPOTECAN

托泊替康最近获得FDA批准 （9-二甲氨基甲基-10羟基喜树碱）和喜树碱（CPT-11） 沿着相关喜树碱的临床开发加速 药物为成功治疗人类癌症提供了新的希望， 包括目前没有有效治疗的肿瘤。 拓扑替康的一种批准用途是用于治疗卵巢癌。 然而，拓扑替康具有窄的治疗范围。 为此，委员会建议， 技术进步，提供了直接和快速的手段， 测量血浆药物水平将是非常有用的。 我们进行 人血浆中拓扑替康和SN-38的直接荧光研究， 使用双光子以微摩尔水平测定全血中的拓扑替康 在730和820 nm处激发。 由于皮肤、血液和其他组织 半透明的长波长，我们的研究结果表明，有吸引力的 同质或非侵入性临床感测的可能性 喜树碱在原位使用双光子激发。

Recent FDA-approval of topotecan (9-dimethylaminomethyl-10hydroxycamptohecin) and camptosar (CPT-11) along with accelerated clinical development of related camptothecin drugs provides new hope for the successful treatment of human cancer, including neoplasms for which no effective treatment currently exist. One approved use of topotecan is for treatment of ovarian cancer. However, topotecan has a narrow therapeutic range. To this end, technological advances, which provide a direct and rapid means of measuring plasma drug levels would be of great utility. We performed direct fluorescence studies of topotecan and SN-38 in human plasma and topotecan in whole blood at micromolar level using two-photon excitation at 730 and 820 nm. Since skin, blood and other tissues are translucent at long wavelength, our results suggest the attractive possibility of homogenous or noninvasive clinical sensing of camptothecins in situ using two-photon excitation.